The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Becton Dickinson announced on Monday that it has inked a deal with Accelerate Diagnostics to sell that firm's Accelerate Pheno system and the Accelerate Arc module for antimicrobial susceptibility testing.

The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has agreed to acquire 100 percent of Albumedix Ltd. from private investors.

Kingmed and Cephei China dsigned a strategic cooperation agreement in Guangzhou to jointly promote the accurate diagnosis of clinical infectious diseases such as tuberculosis, hospital-acquired infection, drug-resistant bacterial infection, and carry out long-term in-depth cooperation.

Guardant Health and Thermo Fisher Scientific said on Friday that the US Food and Drug Administration has granted premarket approvals for their respective next-generation sequencing assays as companion diagnostics to Enhertu (trastuzumab deruxtecan)

Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai said on Friday that they have launched a new large-scale human genome sequencing research project with New York-based biotechnology company Regeneron.

According to the news on August 8, Beijing Savant Biotechnology Co., ltd. (Stock Code No.: 873748) was listed on the New OTC Market.

Lucira Health announced on Thursday that it has received authorization under an interim order from Health Canada to market the Lucira COVID-19 & Flu Test for emergency use.

Roche announced on Thursday that it has received approval from the US Food and Drug Administration for a label expansion of its Ventana MMR RxDx Panel to determine which solid tumor patients could benefit from treatment with Merck's Keytruda (pembrolizumab).

Recently, Suzhou Hybiome Biomedical Engineering Co., Ltd. announced the completion of the Pre-IPO round of financing with CNY 100 million. Huatai United Securities acted as the financial advisor in this transaction and introduced investor Zhongrong Trust Dingxin to Hybiome.

Becton Dickinson announced on Tuesday that it has signed a collaboration agreement with Laboratory Corporation of America to develop flow cytometry-based companion diagnostics.